Evidence map›Paper›PMID 37109596›Full record

ArticleLife (Basel, Switzerland)2023

Celecoxib, a Non-Steroidal Anti-Inflammatory Drug, Exerts a Toxic Effect on Human Melanoma Cells Grown as 2D and 3D Cell Cultures.

Alessandro Venuta, Rosarita Nasso, Armando Gisonna, Roberta Iuliano, Sara Montesarchio, Vittoria Acampora, Leandra Sepe, Angelica Avagliano, Rosaria Arcone, Alessandro Arcucci and 1 more

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. International journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Neutrophils and Anesthetic Drugs: Implications in Onco-Anesthesia.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Alessandro VenutaDepartment of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Rosarita NassoDepartment of Movement Sciences and Wellness, University of Naples "Parthenope", 80133 Naples, Italy.
Armando GisonnaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Roberta IulianoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Sara MontesarchioDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Vittoria AcamporaDepartment of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Leandra SepeDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0001-6669-2503
Angelica AvaglianoDepartment of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Rosaria ArconeDepartment of Movement Sciences and Wellness, University of Naples "Parthenope", 80133 Naples, Italy.
Alessandro ArcucciDepartment of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Maria Rosaria RuoccoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
University of Naples Federico II · ITParthenope University of Naples · IT

Funding

Regione Campania "SATIN" grant 2018-2020
6 · The paper itself

Abstract

Cutaneous melanoma (CM) remains one of the leading causes of tumor mortality due to its high metastatic spread. CM growth is influenced by inflammation regulated by prostaglandins (PGs) whose synthesis is catalyzed by cyclooxygenases (COXs). COX inhibitors, including non-steroidal anti-inflammatory drugs (NSAIDs), can inhibit tumor development and growth. In particular, in vitro experiments have shown that celecoxib, a NSAID, inhibits the growth of some tumor cell lines. However, two-dimensional (2D) cell cultures, used in traditional in vitro anticancer assays, often show poor efficacy due to a lack of an in vivo like cellular environment. Three-dimensional (3D) cell cultures, such as spheroids, are better models because they can mimic the common features displayed by human solid tumors. Hence, in this study, we evaluated the anti-neoplastic potential of celecoxib, in both 2D and 3D cell cultures of A2058 and SAN melanoma cell lines. In particular, celecoxib reduced the cell viability and migratory capability and triggered the apoptosis of melanoma cells grown as 2D cultures. When celecoxib was tested on 3D melanoma cell cultures, the drug exerted an inhibitory effect on cell outgrowth from spheroids and reduced the invasiveness of melanoma cell spheroids into the hydrogel matrix. This work suggests that celecoxib could represent a new potential therapeutic approach in melanoma therapy.

Indexed as

celecoxibmelanomanon-steroidal anti-inflammatory drugsthree-dimensional (3D) cell culturestwo-dimensional (2D) cell cultures

Identifiers

PMID37109596
PMCPMC10141119
OpenAlexW4366772407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.